On April 6, 2026, Artelo Biosciences, Inc. confirmed it regained compliance with Nasdaq's equity requirement of $2.5 million in stockholders’ equity and the annual meeting rule. This ensures continued listing on Nasdaq, but the company will be monitored for one year to maintain compliance.